Assembly Biosciences Inc
ASMB.N- Latest Trade
- trading higher2.14USD
- Change
- 0.02
- % Change
0.71%Positive
- Day Range
- 2.10 - 2.17
- 52-Week Range
- 1.33 - 3.98
As of Jun 30 2022. Values delayed up to 15 minutes
- Previous Close
- 2.13
- Open
- 2.12
- Volume
- 13,073.00
- 3 Month Average Trading Volume
- 10.21
- Shares Out (Mil)
- 48.22
- Market Cap
- 102.22
- Forward P/E
- -1.10
- Dividend Yield
- -99,999.99
Key Statistics
2.2 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 16.34
- Price To Book (Quarterly)
- 0.69
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -60.39
- Return On Equity (TTM)
- -56.95
2021 (millions USD)
About Assembly Biosciences Inc
Company Information
Assembly Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Address
99 HUDSON STREET, 5TH FLOORNEW YORK, NY
10013
United States
Industry
Business Services
Executive Leadership
- William R. Ringo
- Non-Executive Independent Chairman of the Board
- John G. Mchutchison
- President, Chief Executive Officer, Director
- Michael P. Samar
- Chief Financial Officer
- Jason A. Okazaki
- Chief Operating Officer
- William E. Delaney
- Chief Scientific Officer
- Luisa M. Stamm
- Chief Medical Officer
- Nicole S. White
- Chief Manufacturing Officer
- Anthony E. Altig
- Independent Director
- Gina Consylman
- Independent Director
- Richard D. DiMarchi
- Independent Director
- Michael Houghton
- Independent Director
- Lisa R. Johnson-pratt
- Independent Director
- Susan M. Mahony
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,813.70 | -- |
| Copper | 694.25 | -- |
| Brent Crude Oil | 116.07 | 0.16%Negative |
| CBOT Soybeans | 1,671.00 | 0.19%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,818.83 | 0.07%Negative |
| Euro STOXX 50 | 3,514.32 | -- |
| FTSE 100 | 7,312.32 | 0.15%Negative |
| Nikkei 225 | 26,398.76 | 1.51%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes